JPWO2022247816A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022247816A5
JPWO2022247816A5 JP2024515728A JP2024515728A JPWO2022247816A5 JP WO2022247816 A5 JPWO2022247816 A5 JP WO2022247816A5 JP 2024515728 A JP2024515728 A JP 2024515728A JP 2024515728 A JP2024515728 A JP 2024515728A JP WO2022247816 A5 JPWO2022247816 A5 JP WO2022247816A5
Authority
JP
Japan
Prior art keywords
group
general formula
cancer
salt
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515728A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024519188A5 (https=
JP2024519188A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2022/094612 external-priority patent/WO2022247816A1/zh
Publication of JP2024519188A publication Critical patent/JP2024519188A/ja
Publication of JP2024519188A5 publication Critical patent/JP2024519188A5/ja
Publication of JPWO2022247816A5 publication Critical patent/JPWO2022247816A5/ja
Pending legal-status Critical Current

Links

JP2024515728A 2021-05-24 2022-05-24 含窒素複素環系化合物、その調製方法及びその医薬的応用 Pending JP2024519188A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN202110565410.0 2021-05-24
CN202110565410 2021-05-24
CN202110694022 2021-06-22
CN202110694022.2 2021-06-22
CN202110856289 2021-07-28
CN202110856289.7 2021-07-28
CN202210198679 2022-03-02
CN202210198679.4 2022-03-02
PCT/CN2022/094612 WO2022247816A1 (zh) 2021-05-24 2022-05-24 含氮杂环类化合物、其制备方法及其在医药上的应用

Publications (3)

Publication Number Publication Date
JP2024519188A JP2024519188A (ja) 2024-05-08
JP2024519188A5 JP2024519188A5 (https=) 2025-06-03
JPWO2022247816A5 true JPWO2022247816A5 (https=) 2025-06-03

Family

ID=84229501

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515728A Pending JP2024519188A (ja) 2021-05-24 2022-05-24 含窒素複素環系化合物、その調製方法及びその医薬的応用

Country Status (11)

Country Link
US (1) US20240287094A1 (https=)
EP (1) EP4349836A4 (https=)
JP (1) JP2024519188A (https=)
KR (1) KR20240012437A (https=)
CN (1) CN117177971A (https=)
AU (1) AU2022280845A1 (https=)
BR (1) BR112023022496A2 (https=)
CA (1) CA3219858A1 (https=)
MX (1) MX2023013890A (https=)
TW (1) TW202313630A (https=)
WO (1) WO2022247816A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230159525A1 (en) 2021-10-01 2023-05-25 Xinthera, Inc. Azetidine and pyrrolidine parp1 inhibitors and uses thereof
AU2023209820B2 (en) 2022-01-21 2024-10-10 Xinthera, Inc. Parp1 inhibitors and uses thereof
KR20240161147A (ko) 2022-03-14 2024-11-12 슬랩 파마슈티컬스 엘엘씨 다중 사이클릭 화합물
FI4497438T3 (fi) 2022-04-28 2025-10-20 Xinthera Inc Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja
WO2024041643A1 (zh) * 2022-08-25 2024-02-29 江苏恒瑞医药股份有限公司 稠合三环类化合物、其制备方法及其在医药上的应用
CN120035596A (zh) * 2022-11-23 2025-05-23 江苏恒瑞医药股份有限公司 一种含氮杂环类化合物的可药用盐、晶型及制备方法
AU2024286996A1 (en) 2023-06-08 2026-01-08 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Preparation method for formamide compounds
CN120677162A (zh) * 2023-06-13 2025-09-19 中国医药研究开发中心有限公司 含氮杂环类化合物及其医药用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4138564A (en) 1977-08-03 1979-02-06 American Home Products Corporation Tetrahydro[1H]pyrazino[1,2-a]azaquinoxalin-5(6H)-ones and derivatives thereof
AUPS137402A0 (en) * 2002-03-26 2002-05-09 Fujisawa Pharmaceutical Co., Ltd. Novel tricyclic compounds
US8299256B2 (en) 2007-03-08 2012-10-30 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP and TANK inhibitors
US8404713B2 (en) 2007-10-26 2013-03-26 Janssen Pharmaceutica Nv Quinolinone derivatives as PARP inhibitors
CN102372716A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光a激酶抑制劑
JP7469304B2 (ja) * 2018-11-16 2024-04-16 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 Parpインヒビタを含む医薬組成物
MX2022000711A (es) * 2019-07-19 2022-02-23 Astrazeneca Ab Inhibidores de parp1.
CN116018132A (zh) 2020-06-24 2023-04-25 Itf研究制药有限公司 软明胶胶囊
US11795158B2 (en) 2020-06-25 2023-10-24 Astrazeneca Ab Chemical compounds
TW202309025A (zh) * 2021-04-19 2023-03-01 美商辛瑟拉股份有限公司 Parp1抑制劑及其用途
CN119110801A (zh) * 2022-05-07 2024-12-10 南京明德新药研发有限公司 选择性抑制parp1的氟代喹喔啉酮衍生物

Similar Documents

Publication Publication Date Title
JPWO2021083949A5 (https=)
Quirante et al. Platinum (II) and palladium (II) complexes with (N, N′) and (C, N, N′)− ligands derived from pyrazole as anticancer and antimalarial agents: Synthesis, characterization and in vitro activities
US4140707A (en) Malonato platinum anti-tumor compounds
CN115697993A (zh) 作为axl抑制剂的嘧啶类化合物
CN111295384A (zh) 双环类衍生物抑制剂、其制备方法和应用
JP2010531304A5 (https=)
JPWO2022247816A5 (https=)
CS239911B2 (en) Processing of complexed diamino platinum
JP2013532668A5 (https=)
JP3200421B2 (ja) 化学療法剤としての新規ビス白金錯体
RU2000125568A (ru) Производные циклоалкенов, их получение и применение
JP2018504441A5 (https=)
JP2012523418A5 (https=)
CA2514977A1 (en) Polymorph of {6,7-bis(2-methoxy-ethoxy)-quinazolin-4-yl}-(3e)
WO1990005734A1 (en) Water soluble 1,2-diaminocyclohexane platinum (iv) complexes as antitumor agents
JPWO2021086785A5 (https=)
JPWO2020247496A5 (https=)
JP2025111532A (ja) 5-ブロモピリジン-3-イル-3-デオキシ-3-[4-(3,4,5-トリフルオロフェニル)-1h-1,2,3-トリアゾール-1-yl]-1-チオ-アルファ-d-ガラクトピラノシド及びその結晶形を調製するための大規模方法
Ozdemir et al. Synthesis, anticonvulsant and antimicrobial activities of some new [1-(2-naphthyl)-2-(pyrazol-1-yl) ethanone] oxime ethers
EP2227479B1 (de) CYCLOPENTADIENYLPHOSPHAZEN-KOMPLEXE (CpPN-KOMPLEXE) VON METALLEN DER 3. UND 4. GRUPPE UND DER LANTHANOIDE
JPWO2022246177A5 (https=)
KR102252540B1 (ko) 벤조사이아졸 유도체가 결합된 리간드-금속 복합체 및 이의 제조 방법
Prater et al. A quadruply-bonded dirhenium complex bridged by two N1/N6 adenate ligands
JP5449769B2 (ja) モノニトリル含有リガンドを有する白金錯体
Filipović et al. Silver-based monomer and coordination polymer with organic thiocyanate ligand: Structural, computational and antiproliferative activity study